target upgrad unit state go sg websit
softer sale better-than-expect earn fy guidanc narrow
upsid tp
report lower-than-expect revenu larg due
expect ep lower tax rate despit softer oper
incom manag narrow full year ep guidanc rang
sale new product legaci portfolio expect pfizer
sale grew constant exchang rate cer
consensu estim howev adjust ep consensu
nc chang
mainli due lower tax even though oper profit slightli estim due
pharma sale new product cancer ibranc xalkori inflamm xeljanz
consensu expect respect sale
legaci portfolio sale declin howev prevnar vaccin enbrel
previou gener immune-inflamm drug better expect
expect respect despit biosimilar competit europ latter
guidanc narrow sale earn per share compani narrow
guidanc sale low end rang ep mid-point unchang
reflect declin perform hospira steril inject sale due
drug shortag us currenc impact mainli emerg currenc revis
guidanc follow sale vs non-
ep vs expect limit impact consensu
forecast compani share repurchas programm expect amount
year vs interestingli confer call manag stress
dont need larg prefer reli robust pipelin howev dont
think rule option given track record
hold reiter tp increas attract new product cancer
inflamm wont enough re-energ top line low single-digit growth vs
sector group trade discount vs peer price-to-earnings despit
slower growth ep compound-annual-growth-rate vs adjust estim
reflect result updat target price
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
simplifi main product divis
sell inform administr
net incom attribut pfizer inc
confer call feedback strong pipelin negat need larg
innov medicin continu main driver growth total sale exclud
consum health busi oper growth due strong perform new
product ibranc oncolog total sale yoy oper growth xeljanz
inflamm sale oper growth eliqui anticoagul sale
howev growth factor partial off-set neg effect lose exclus
viagra declin legaci establish medicin sale oper growth
industry-wid price challeng product suppli shortag relat hospira product
 compani see need large-scal time instead
concentr pipelin gener growth post howev believ
remain option compani opportun appear would potent way
gener bottom-lin growth compani enjoy sold track record front
sale divis total revenu
sg cross asset research/equity/ innov inclus consum
new product ibranc breast cancer littl less share new prescript
volum manag retain leadership posit inhibitor class us sinc
launch around patient us patient eu treat
accord manag growth driver still intern market particularli eu
japan product well track super-blockbust statu market
expect alreadi high beyond see limit upsid surpris
similarli xeljanz bolster launch new indic psoriat arthriti ulcer
coliti continu well script yoy
essenti apart on-going suppli shortag steril inject busi
essenti busi advers affect continu loss exclus especi
lyrica europ howev manag focus make establish busi
robust enhanc autonomi
consum yoy oper growth manag review option
respect divis make decis end calendar year believ
dispos credibl scenario doubt compani would get offer sale
use sum part
price manag still believ rebat point-of-purchas lower price
drug benefici patient like potenti new rule
part name import price control compani continu price valu
product price insid competit marketplac manag assess situat
januari take decis evalu valu proposit new market place
medium-term strategi sale growth establish product busi
contribut china growth yoy compani reloc
manag china nearer market manag growth opportun
better compani believ take leadership posit fast-grow segment
realis vision provid establish product busi substanti
tp increas vs
part
averag pharma premium innov
vaccin consum discount matur portfolio
adjust earn estim reflect result trend tp increas
reflect chang plu higher pharma sector multipl due recent rerat
adjust assumpt lt margin higher premium innov
america
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet oct cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
averag sotp averag ev/ebita us pharma multipl appli estim ebita subdivis discount
tail portfolio premium innov product premium vaccin consum reflect visibl growth profil
dcf lt growth lt ebita margin
main risk faster eros establish product high singl digit impact ebit stronger biosimilar impact
enbrel low singl digit impact tougher ibranc competit landscap breast cancer low singl digit impact upsid risk stronger
success ibranc doubl digit impact
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
sg act joint bookrunn bond issu
sg act joint lead manag european union outstand tap bond issu
sg act co-manag novarti financ sa bond issu senior
sg act global co-ordin sanofi multi-tranch senior bond issu eur yr yr yr yr yr yr
